Survival
Primary Peritoneal Mesothelioma Affecting the Greater Omentum That Mimicked an Omental Infarction: A Case Report
Case Reports in Oncology 2024 May 30 [Link] John Corbyn Cravero, Taylor Yakubik, Laith Wahab, Thao Giang, Lisa M Lopez, Megan G Newman Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a rare cancer that is associated with asbestos exposure. The diagnosis can be difficult given the nonspecific nature of presenting symptoms and the presence of…
Read MoreContemporary management of mesothelioma
Breathe 2024 July 16 [Link] Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth Abstract Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are…
Read MoreIntegration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study
PloS One 2024 July 15 [Link] Jolien Van den Bossche, Maxime De Laere, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille, Eva Lion, Zwi Berneman Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint…
Read MoreThonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling
Cancer Cell International 2024 June 29 [Link] Irene Dell’Anno, Federica Morani, Simone Patergnani, Antonio Daga, Paolo Pinton, Carlotta Giorgi, Luciano Mutti, Federica Gemignani, Stefano Landi Abstract Background: Malignant Pleural Mesothelioma (MPM) is a rare malignancy with a poor prognosis. Current therapies are unsatisfactory and novel cures are urgently needed. In a previous drug screening, we…
Read MoreComprehensive Pulmonary Rehabilitation for Patients with Malignant Pleural Mesothelioma: A Feasibility Pilot Study
Cancers 2024 May 26 [Link] Lorenzo Lippi, Alessandro de Sire, Arianna Folli, Claudio Curci, Dario Calafiore, Mariano Lombardi, Luca Bertolaccini, Alessio Turco, Antonio Ammendolia, Nicola Fusco, Lorenzo Spaggiari, Marco Invernizzi Abstract Malignant pleural mesothelioma (MPM) represents a significant health burden, with limited treatment options and poor prognosis. Despite advances in pharmacological and surgical interventions, the…
Read MoreDendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study
The Lancet Oncology 2024 June 4 [Link] Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen, Jan P van Meerbeeck Abstract Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We aimed…
Read MoreImmediate Versus Deferred Systemic Therapy in Patients With Mesothelioma
Clinical Lung Cancer 2024 April 20 [Link] Sabine Schmid, Luna Zhan, Miguel Garcia, Kristen Dietrich, Khaleeq Khan, Maisha Chowdhury, Michael Herman, Devalben Patel, Fatemeh Zaeimi, Natasha B Leighl, Adrian Sacher, Ronald Feld, Frances A Shepherd, Laura Donahoe, Marc de Perrot, B C John Cho, Geoffrey Liu, Penelope A Bradbury Abstract Background: The 2018 ASCO pleural…
Read MoreComparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
Thoracic Cancer 2024 June 5 [Link] Xuemei Zhang, Lele Chang, Qian Ma, Qian Zhang, Wansu Xu, Qingwei Li Abstract Background: This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real-world diffuse pleural mesothelioma patients in China. Methods: Clinical data of 90 patients with diffuse pleural mesothelioma…
Read MoreCurrent clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Innovative Surgical Sciences 2024 March 14 [Link] Miklos Acs, Maximilian Babucke, Maximilian Jusufi, Zsolt Kaposztas, Przemyslaw Slowik, Matthias Hornung, Hans J Schlitt, Ivan Panczel, Judit Hevesi, Jonas Herzberg, Tim Strate, Pompiliu Piso Abstract Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled problems, as there are many uncertain aspects considering the outcomes of…
Read MoreFK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology
Molecular Medicine 2024 May 31 [Link] James Mei-Lin Chan, Yuan-Ching Chang, Hua-Chen Chan, Hsiu-Chuan Chan, Wei-Chin Chang, Liu-Fang Wang, Tung-Hu Tsai, Yu-Jen Chen, Wen-Chien Huang Abstract Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally…
Read More